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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to carry out a supplementary safety assessment for taxifolin by
considering also those population groups which were originally excluded at the request of the applicant
(i.e. infants, young children and children up to 9 years) for the food categories set out in the
application, and by taking into the extension of use of taxifolin from yogurt to a wider range of dairy
products. In 2016, the EFSA NDA Panel adopted the Scientiﬁc Opinion on the safety of taxifolin-rich
extract from Dahurian Larch (Larix gmelinii) as a novel food ingredient in non-alcoholic beverages,
yogurts, chocolate confectionery and food supplements pursuant to Regulation (EC) No 258/97. In
order to address the present mandate, an intake assessment was carried out by taking into account all
population groups (including now also children below 9 years of age) and by considering the food
intended categories for which the applicant provided maximum use levels of taxifolin. Intakes were
estimated for all age groups of the general population. The highest 95th percentile intakes per kg bw
per day among all population groups are 0.94 and 1.54 mg, respectively, derived for toddlers. Noting
that the no-observed-adverse effect level (NOAEL) of the subchronic study was 1,500 mg/kg body
weight (bw), the resulting margin of exposure (MOE) would be almost 1,000. For adults weighing
70 kg, the MOE to the combined intake from fortiﬁed foods and food supplements would be about
772. For adolescents, taking into account a default mean body weight of 61 kg, the MOE to the
combined intake (including 100 mg from food supplements) would be about 627. The Panel considers
that these MOEs are sufﬁcient. The Panel concludes that the NF food, taxifolin-rich extract from
Dahurian Larch, is safe under the proposed conditions of use.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to carry out a supplementary safety assessment for taxifolin by
considering also those population groups which were originally excluded at the request of the applicant
(i.e. infants, young children and children up to 9 years) for the food categories set out in the
application, and by taking into the extension of use of taxifolin from yogurt to a wider range of dairy
products.
On 13 December 2016, the EFSA NDA Panel adopted the Scientiﬁc Opinion on the safety of
taxifolin-rich extract from Dahurian Larch (Larix gmelinii) as a novel food ingredient in non-alcoholic
beverages, yogurts, chocolate confectionery and food supplements pursuant to Regulation (EC)
No 258/971 (EFSA NDA Panel et al., 2016). In order to address the present mandate, an intake
assessment was carried out by taking into account all population groups (including now also children
below 9 years of age) and by considering the food intended categories for which the applicant
provided maximum use levels of taxifolin. The intended food categories for the extended proposed use
of taxifolin were allocated to corresponding food categories of the EFSA Comprehensive Food
Consumption Database (EFSA, 2011) which is based on data from EU Member States’ dietary surveys.
Mean and high intakes (i.e. 95th percentile) were estimated for ‘all subjects’ for all age groups of the
general population by using individual data of that data base and assuming that all foods of the
intended food categories contain taxifolin at the maximum proposed use levels.
The highest mean and 95th percentile intakes per kg bw per day among all population groups are
0.94 and 1.54 mg, respectively, derived for toddlers. Noting that the NOAEL of the 90-day subchronic
study was 1,500 mg/kg body weight (bw), the resulting margin of exposure (MOE) to the 95th
percentile intake estimate for toddlers would be almost 1,000. For adults weighing 70 kg, the MOE to
the combined intake from fortiﬁed foods and food supplements would be about 772. For adolescents,
taking into account a default mean body weight of 61 kg, the MOE to the combined intake (including
100 mg from food supplements) would be about 627. The Panel considers that these MOEs are
sufﬁcient.
The Panel concludes that the NF food, taxifolin-rich extract from Dahurian Larch, is safe under the
proposed conditions of use.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
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1. Introduction
1.1. Background
On 13 December 2016, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) adopted
the Scientiﬁc Opinion on the safety of taxifolin-rich extract from Dahurian Larch (Larix gmelinii) as a
novel food ingredient in non-alcoholic beverages, yogurts, chocolate confectionery and food
supplements pursuant to Regulation (EC) No 258/971 (EFSA NDA Panel, 2016).
The request for the supplementary assessment followed the comments raised by some Member
States at the Standing Committee regarding the potential for exposure of the excluded population
subgroups (i.e. infants, young children and children up to 9 years) to taxifolin from the consumption of
food products containing taxifolin. Their concerns stem from the fact that although the use of taxifolin
has been assessed by the European Food Safety Authority (EFSA) to be safe for the intended uses set
out in the application, in real life situations, it would be difﬁcult to ensure that those products (e.g.
chocolate, yogurt, non-alcoholic beverages) will not be consumed by the excluded subgroups of the
population. Consequently, an exposure and safety assessment is needed for these subgroups. In
addition, the applicant requested to expand the use of taxifolin to all types of dairy products, not just
yogurts and submitted an extended intake estimate to cover other dairy products.
1.2. Terms of Reference as provided by the European Commission
Consequently, EFSA was asked to update the former dietary exposure and safety assessment for
taxifolin in order to consider:
1) The groups of the population which were excluded in the application of taxifolin as a novel
food ingredient in the context of Regulation (EC) No 258/97, namely, infants, young children,
and children up to nine years of age for all food products in the application (i.e. non-
alcoholic beverages, yogurt and chocolate confectionary).
2) All groups of the population for all types of dairy products.
2. Data and methodologies
2.1. Data
The assessment of the safety of taxifolin at the extended uses for all groups of the general
population is based on supplementary information to original novel food (NF) application (i.e. Dossier
‘Taxifolin’) provided by the applicant, the EFSA Comprehensive Food Consumption Database (EFSA,
2011) and the scientiﬁc opinion on the safety of taxifolin (EFSA NDA Panel, 2016).
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
On 13 December 2016, the EFSA NDA Panel adopted the Scientiﬁc Opinion on the safety of taxifolin-
rich extract from Dahurian Larch (Larix gmelinii) as a novel food ingredient in non-alcoholic beverages,
yogurts, chocolate confectionery and food supplements pursuant to Regulation (EC) No 258/971 (EFSA
NDA Panel, 2016). The maximum use levels proposed by the applicant were 0.02 g/L for non-alcoholic
beverages, 0.02 g/kg for yogurts and 0.07 g/kg for chocolate confectionery. The maximum proposed
daily intake of taxifolin from food supplements was 100 mg/day. According to the applicant, taxifolin
was intended for the general population from the age of 9 years onwards with the exception of its use
for food supplements which are not intended for children of below 14 years of age. For estimating
intakes of taxifolin by the target population, the applicant used the summary statistics of the EFSA
Comprehensive Food Consumption Database (EFSA, 2011). The approach applied by the applicant
included several conservative elements as outlined in the EFSA Opinion (estimating all ‘ﬂavoured
fermented milk and dairy products’ as a whole food category instead of ‘yogurt’, assessing ‘consumers
Safety of taxifolin
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only’ and summing up the high percentile consumption of each food category for deriving the high
percentiles for the total intake from all categories). In 2016, the Panel considered that the highest dose
tested in the 90-day subchronic rat study, i.e. 1,500 mg/kg bodyweight (bw) per day, was the
no-observed-adverse effect level (NOAEL) of this study (Tselyico, 2016 – unpublished study report).
The Panel concluded that the margins of exposure (MOEs) of this NOAEL and the estimated intake of
taxifolin from the intended food uses (including 100 mg taxifolin/ day from supplements) were 660 for
adults consuming 158 mg/day and 460 for adolescents consuming 146 mg/day, respectively. The
Panel concluded that the NF, taxifolin-rich extract from Dahurian Larch, is safe under the proposed
conditions of use (EFSA NDA Panel, 2016).
In order to address the present mandate, an intake assessment was carried out by taking into
account all population groups (including now also children below 9 years of age) and by considering
the food intended categories for which the applicant provided maximum use levels of taxifolin.
3.1. Anticipated intake/extent of use
Different from the original application assessed in 2016, the applicant intends to use taxifolin in the
category ‘dairy’ not only for yogurts, but for a wider range of dairy products as presented in Table 1.
This table contains also intended maximum use levels of taxifolin for these products. It is noted that
the intended uses and use levels of taxifolin in chocolate confectionery and non-alcoholic beverages
remain unchanged from the original application. The Panel also notes that taxifolin has been
authorised for its use in food supplements excluding children younger than 14 years with and limited
to an intake of 100 mg/day.
3.1.1. Intake from fortiﬁed foods
The intended food categories for the extended proposed use of taxifolin were allocated to
corresponding food categories (Table 2) of the EFSA Comprehensive Food Consumption Database
(EFSA, 2011) which is based on data from EU Member States’ dietary surveys.
Table 1: Proposed uses and use levels for taxifolin
Food products
Applicant’s assumptions
of the fat content in the
products (%)
Use of taxifolin
in % by fat
mass
Maximum use levels
proposed by the
applicant
Cowmilk yogurt, plain 10 0.02 0.020 g/kg
Cowmilk yogurt with fruits 10 0.02 0.020 g/kg
Keﬁr 3.2 0.025 0.008 g/kg
Buttermilk 2 0.025 0.005 g/kg
Dried milk 26 0.02 0.052 g/kg
Cream 30 0.025 0.070 g/kg
Sour cream 20 0.025 0.050 g/kg
Cheese 45 0.02 0.090 g/kg
Butter 82 0.02 0.164 g/kg
Chocolate confectionery 35 0.02 0.070 g/kg
Non-alcoholic beverages – – 0.020 g/L
Table 2: Extended intended uses and use levels for the NF as a food ingredient
Food category used for the EFSA Comprehensive Data Base Use levels
Unﬂavoured fermented milk products, including natural unﬂavoured buttermilk
(excluding sterilised buttermilk) non heat-treated after fermentation
0.020 g/kg
Flavoured fermented milk products including heat-treated products 0.020 g/kg
Dehydrated milk 0.052 g/kg
Cream and cream powder 0.070 g/kg
Cheese and cheese products 0.090 g/kg
Unripened cheese 0.090 g/kg
Ripened cheese 0.090 g/kg
Safety of taxifolin
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Mean and high intakes (i.e. 95th percentile) were estimated for ‘all subjects’ for all age groups of
the general population by using individual data of that data base and assuming that all foods of the
intended food categories contain taxifolin at the maximum proposed use levels. The ranges of the
estimated mean and high intakes (in mg/kg bw per day) among the individual EU dietary surveys for
the various population groups are presented in Table 3.
The highest mean and highest 95th percentile intakes per kg bw per day among all population
groups are 0.94 and 1.54 mg, respectively, derived for toddlers.
3.1.2. Combined intake from fortiﬁed foods and food supplements
Considering the highest 95th percentile intake for adults from fortiﬁed food (i.e. 0.52 mg/kg bw per
day) and a default bodyweight of 70 kg for an adult (EFSA Scientiﬁc Committee, 2012), the combined
taxifolin intake from fortiﬁed foods (36 mg) and from food supplements (100 mg), is estimated at
136 mg/day.
When considering the highest 95th percentile intake for adolescents from fortiﬁed food (i.e.
0.76 mg/kg bw per day) and a default mean body weight of 61 kg for adolescents of 14–18 years
(EFSA Scientiﬁc Committee, 2012), combined taxifolin intake from fortiﬁed foods (46 mg) and from
food supplements (100 mg), results to 146 mg taxifolin intake per day. The Panel notes that in its
Opinion from 2016 a lower default body weight (45 kg, i.e. P5 according to EFSA Scientiﬁc Committee,
2012) was considered for the target group of adolescents between 14 and 18 years of age accounting
for the use of consumption data of adolescents between 10 and 17 years of age and thus included
children below 14 years of age with a lower food intake per person and lower body weight.
Also, the intake estimate for taxifolin from fortiﬁed food for adolescents of the present evaluation is
based on consumption data of the population group between 10 and 17 years of age, but on per kg
bw base and thus includes consumption data for younger children below 14 years with higher food
intake per kg bw than adolescents from 14 years onwards. Therefore, multiplying the default body
weight of 61 kg for adolescents from 14 years onwards with food consumption data on a per kg bw
base from the population group 10–17 years of age, is considered conservative.
Food category used for the EFSA Comprehensive Data Base Use levels
Whey cheese 0.090 g/kg
Processed cheese 0.090 g/kg
Fats and oils essentially free from water (excluding anhydrous milkfat) 0.164 g/kg
Cocoa and Chocolate products 0.070 g/kg
Fruit juices as 0.020 g/L
Vegetable juices 0.020 g/L
Fruit nectars and vegetable nectars and similar products 0.020 g/L
Flavoured drinks with sugar 0.020 g/L
Flavoured drinks with sweetener 0.020 g/L
Table 3: Intake estimates for taxifolin on the basis of proposed uses and use levels
Population group
Range of means
(mg/kg bw per day)
Range of high intakes
(95th percentile)(a)
(mg/kg bw per day)
Infants (up to 1 year) 0.12–0.34 0.32–0.74
Toddlers (1–3 years) 0.34–0.94 0.74–1.54
Other children (4–9 years) 0.28–0.73 0.66–1.47
Adolescents (10-17 years) 0.19–0.39 0.36–0.76
Adults (18–64 years) 0.09–0.22 0.24–0.52
Elderly (> 64 years) 0.05–0.17 0.13–0.32
bw: body weight.
(a): Based on surveys with > 60 consumers
Safety of taxifolin
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4. Discussion
The highest intake estimate per kg bw intake of taxifolin per day from fortiﬁed foods among all
groups of the general population is derived for toddlers (1–3 years) and children of 4–9 years of age
at approximately 1.5 mg/kg bw per day. Noting that the NOAEL of the 90-day subchronic study
(Tselyico, 2016 – unpublished study report) was 1,500 mg/kg bw, the resulting MOE would be about
1,000 for these age groups. The MOE for infants and for children between 10 and 13 years of age
would be approximately 2000.
For adults weighing 70 kg, the MOE to the combined intake from fortiﬁed foods and food supplements
would be about 770. For adolescents, taking into account a default body weight of 61 kg (mean body
weight for adolescents aged 14–18 years as suggested by EFSA Scientiﬁc Committee (2012)), the MOE to
the combined intake (including 100 mg from food supplements) would be about 630.
The Panel considers that these MOEs are sufﬁcient.
5. Conclusions
The Panel concludes that the NF food, taxifolin-rich extract from Dahurian Larch, is safe under the
proposed conditions of use.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request to carry out a supplementary dietary exposure and safety assessment to
L-ergothioneine. Ref. Ares(2017)3243708, dated 28/6/2017.
2) Supplementary information from the applicant including information on extended uses and a
revised intake estimate.
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